Brooklyn Stock Insiders


USD 0.57  0.03  5.00%   

Brooklyn Immunotherapeuti employes about 10 people. The company is managed by 33 executives with total tenure of roughly 220 years, averaging almost 6.0 years of service per executive having 0.3 employees per reported executive. Break down of Brooklyn Immunotherapeuti management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Brooklyn Immunotherapeuti future performance.
Continue to Trending Equities.
  Michael West  CEO
Co-CEO and President and Director
  Brian Culley  CEO
President CEO, Director
  Pedro Lichtinger  CEO
CEO of Asterias Biotherapeutics Inc and President of Asterias Biotherapeutics Inc

Brooklyn Immunotherapeuti Return on Sales



Brooklyn Immunotherapeuti Management Team Effectiveness

Brooklyn Immunotherapeuti has Return on Asset of (74.2) % which means that on every $100 spent on asset, it lost $74.2. This is way below average. Brooklyn Immunotherapeuti management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -24.25 in 2022. Return on Average Assets is likely to drop to -3.2 in 2022. Brooklyn Immunotherapeuti Current Assets are fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Current Assets of 18.77 Million in 2021. Goodwill and Intangible Assets is likely to rise to about 2.1 M in 2022, whereas Total Assets are likely to drop slightly above 26.9 M in 2022.

Brooklyn Immunotherapeuti Quarterly Total Assets

32.43 Million

Weighted Average Shares is likely to rise to about 46.7 M in 2022. Weighted Average Shares Diluted is likely to rise to about 46.7 M in 2022

Brooklyn Immunotherapeuti Workforce Comparison

Brooklyn Immunotherapeutics is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 20.0. Brooklyn Immunotherapeuti totals roughly 10.0 in number of employees claiming about 50% of stocks in Biotechnology industry.

Brooklyn Immunotherapeuti Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Brooklyn Immunotherapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Brooklyn Immunotherapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Brooklyn Immunotherapeuti insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Brooklyn Immunotherapeuti Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Brooklyn Immunotherapeuti Price Series Summation is a cross summation of Brooklyn Immunotherapeuti price series and its benchmark/peer.

Brooklyn Immunotherapeuti Notable Stakeholders

A Brooklyn Immunotherapeuti stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Brooklyn Immunotherapeuti often face trade-offs trying to please all of them. Brooklyn Immunotherapeuti's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Brooklyn Immunotherapeuti's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael West - Co-CEO and President and DirectorProfile
Brian Culley - President CEO, DirectorProfile
Pedro Lichtinger - CEO of Asterias Biotherapeutics Inc and President of Asterias Biotherapeutics IncProfile
Aditya Mohanty - Co-CEOProfile
Artur Maczynski - Vice Chairman of the Supervisory BoardProfile
Lech Pasturczak - Vice Chairman of the Supervisory BoardProfile
Tomasz Gierczynski - Chairman of the Management BoardProfile
Alfred Kingsley - Chairman of the BoardProfile
Konrad Kosierkiewicz - Chairman of the Supervisory BoardProfile
Brandi Roberts - CFO, Senior Vice President - FinanceProfile
Jim Knight - Senior Vice President-Head of Corporate DevelopmentProfile
Gary Hogge - Senior Vice President of Clinical & Medical AffairsProfile
Russell Skibsted - CFOProfile
Michael Mulroy - DirectorProfile
David Schlachet - DirectorProfile
Don Bailey - DirectorProfile
Stephen Cartt - DirectorProfile
Stephen Farrell - Independent DirectorProfile
Judith Segall - VP of Admin., Secretary and DirectorProfile
Deborah Andrews - DirectorProfile
David Nakasone - Director - Investor RelationsProfile
Neal Bradsher - Independent DirectorProfile
Angus Russell - DirectorProfile
Cavan Redmond - Independent DirectorProfile
Stanislaw Pargiela - Member of the Supervisory BoardProfile
Chase Leavitt - General Counsel and Corporate SecretaryProfile
Matt Haines - IR Contact OfficerProfile
Edward Wirth - OtherProfile
Stephana Patton - General CounselProfile
Dorota Walkiewicz - Member of the Management Board for Administration and OrganizationProfile
Blazej Wisniewski - Member of the Management Board for Finance, Chief Accounting OfficerProfile
Heinz Jammers - Member of the Supervisory BoardProfile
Andrzej Pargiela - Secretary of the Supervisory BoardProfile

About Brooklyn Immunotherapeuti Management Performance

The success or failure of an entity such as Brooklyn Immunotherapeuti often depends on how effective the management is. Brooklyn Immunotherapeuti management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Brooklyn management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Brooklyn management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Investment(22.48) (24.25) 
Return on Average Assets(3.11) (3.20) 
Return on Average Equity(9.73) (9.98) 
Return on Invested Capital(11.73) (12.04) 
Return on Sales(0.10) (0.11) 
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.
The data published in Brooklyn Immunotherapeuti's official financial statements usually reflect Brooklyn Immunotherapeuti's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Brooklyn Immunotherapeuti. For example, before you start analyzing numbers published by Brooklyn accountants, it's critical to develop an understanding of what Brooklyn Immunotherapeuti's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Brooklyn Immunotherapeuti's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Brooklyn Immunotherapeuti's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Brooklyn Immunotherapeuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Brooklyn Immunotherapeutics. Please utilize our Beneish M Score to check the likelihood of Brooklyn Immunotherapeuti's management to manipulate its earnings.

Brooklyn Immunotherapeuti Workforce Analysis

Traditionally, organizations such as Brooklyn Immunotherapeuti use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Brooklyn Immunotherapeuti within its industry.

Brooklyn Immunotherapeuti Manpower Efficiency

Return on Brooklyn Immunotherapeuti Manpower

Revenue Per Employee52.4 K
Revenue Per Executive104.5 K
Net Loss Per Employee464.6 K
Net Loss Per Executive3.7 M
Working Capital Per Employee3.5 M
Working Capital Per Executive1.1 M
Today, most investors in Brooklyn Immunotherapeuti Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Brooklyn Immunotherapeuti's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Brooklyn Immunotherapeuti per employee as a starting point in their analysis.

Per Employee

Brooklyn Immunotherapeuti Per Employee Growth Over Time

Net Income Per Employee


Brooklyn Immunotherapeuti Net Income Per Employee is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Net Income Per Employee of (430,573) in 2021

Revenue Per Employee


Brooklyn Immunotherapeuti Revenue Per Employee is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Revenue Per Employee of 38,075.35 in 2021
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Transaction History
View history of all your transactions and understand their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
33 M
Return On Assets
Return On Equity
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.